ACIP issues interim recommendations for bivalent COVID-19 booster vaccines

The Advisory Committee on Immunization Practices (ACIP) has published interim recommendations for the use of bivalent COVID-19 booster vaccines. This document provides guidance for the United States population but does not constitute a clinical study. No sample size, study setting, comparator groups, or follow-up duration are reported.

No primary or secondary clinical outcomes are presented. The report contains no data on vaccine efficacy, immunogenicity, or clinical endpoints such as infection rates, hospitalization, or mortality. Similarly, no safety or tolerability information is provided, including rates of adverse events, serious adverse events, or discontinuations.

This is solely a recommendations publication. Key limitations include the absence of any clinical trial data, patient outcomes, or safety profiles. The practice relevance is limited to providing interim guidance for vaccine use while awaiting full clinical evidence from ongoing studies.